EGRX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Eagle Pharmaceuticals's net margin of 8.48%. Eagle Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3300%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25.65%. Given that Eagle Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Eagle Pharmaceuticals is more attractive than Eli Lilly and.

Eagle Pharmaceuticals has a beta of 0.677, which suggesting that the stock is 32.269% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Eagle Pharmaceuticals's net income of -- is lower than Eli Lilly and's net income of $970.3M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 84.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.03x versus 17.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Eagle Pharmaceuticals's net margin of -49.65%. Eagle Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3300%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that Eagle Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Eagle Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Eagle Pharmaceuticals has a beta of 0.677, which suggesting that the stock is 32.269% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Eagle Pharmaceuticals's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.03x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Eagle Pharmaceuticals's net margin of -2357.27%. Eagle Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3300%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Eagle Pharmaceuticals has higher upside potential than Palatin Technologies, analysts believe Eagle Pharmaceuticals is more attractive than Palatin Technologies.

Eagle Pharmaceuticals has a beta of 0.677, which suggesting that the stock is 32.269% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Eagle Pharmaceuticals's net income of -- is lower than Palatin Technologies's net income of -$7.8M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Verrica Pharmaceuticals has a net margin of -- compared to Eagle Pharmaceuticals's net margin of -331.97%. Eagle Pharmaceuticals's return on equity of -- beat Verrica Pharmaceuticals's return on equity of -2619.46%.

Eagle Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3300%. On the other hand Verrica Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 825.52%. Given that Eagle Pharmaceuticals has higher upside potential than Verrica Pharmaceuticals, analysts believe Eagle Pharmaceuticals is more attractive than Verrica Pharmaceuticals.

Eagle Pharmaceuticals has a beta of 0.677, which suggesting that the stock is 32.269% less volatile than S&P 500. In comparison Verrica Pharmaceuticals has a beta of 1.401, suggesting its more volatile than the S&P 500 by 40.109%.

Eagle Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verrica Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eagle Pharmaceuticals pays -- of its earnings as a dividend. Verrica Pharmaceuticals pays out -- of its earnings as a dividend.

Eagle Pharmaceuticals quarterly revenues are --, which are smaller than Verrica Pharmaceuticals quarterly revenues of -$1.8M. Eagle Pharmaceuticals's net income of -- is lower than Verrica Pharmaceuticals's net income of -$22.9M. Notably, Eagle Pharmaceuticals's price-to-earnings ratio is -- while Verrica Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eagle Pharmaceuticals is 0.03x versus 3.46x for Verrica Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.